Trésor Zola Matuvanga

Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol

Ynke Larivière, Trésor Zola Matuvanga, Elke Stoppie et al. · BMJ Open · 2021 · 25 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Challenges to COVID-19 vaccine introduction in the Democratic Republic of the Congo – a commentary

Trésor Zola Matuvanga, Reena H. Doshi, Albert Muya et al. · Human Vaccines & Immunotherapeutics · 2022 · 19 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +13

Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study

Trésor Zola Matuvanga, Ginger A. Johnson, Ynke Larivière et al. · Journal of Medical Internet Research · 2021 · 17 citations · Full text

Veterinary Medicine, Health Informatics, Infectious Diseases +17

Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned

Trésor Zola Matuvanga, Ynke Larivière, Gwen Lemey et al. · Vaccine · 2022 · 16 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang’ir et al. · The Lancet Infectious Diseases · 2024 · 16 citations

Veterinary Medicine, Immunology, Infectious Diseases +13